Company intelligence / Profile preview

Wuhan Nature’s Favour

Wuhan, Hubei, China

Ownership: Private
Development stage: Other

Overview

Wuhan Nature's Favour is a clinical-stage biotechnology company specializing in mRNA-based vaccines and therapeutics. Headquartered in Wuhan, China, the company has developed a proprietary lipid nanoparticle (LNP) delivery platform and a comprehensive mRNA technology stack. Its lead program, NF-001, is an mRNA vaccine targeting COVID-19 that has progressed into Phase 2 clinical trials. Beyond infectious diseases, the company is actively developing personalized cancer vaccines and other prophylactic vaccines. Wuhan Nature's Favour focuses on the entire mRNA production cycle, from sequence optimization to large-scale manufacturing.

Therapeutic areas: OncologyInfectious Diseases
Modalities: mRNA-based drugsLipid nanoparticle delivery therapyVaccine
Industry: Biotech

Beyond the preview

Go deeper on Wuhan Nature’s Favour.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wuhan Nature’s Favour.

Explore the full profile